SCHEMBL1725558

SCHEMBL1725558

CC(C)(C)OC(=O)CCn1cc(B2OC(C)(C)C(C)(C)O2)cn1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.57
DGAT1 O75907 1/20 0.38
USP30 Q70CQ3 2/20 0.37
AAK1 Q2M2I8 2/20 0.37
PRMT5 O14744 1/20 0.37
WDR77 Q9BQA1 1/20 0.37
BACE1 P56817 1/20 0.35
BACE2 Q9Y5Z0 1/20 0.35
GSK3A P49840 1/20 0.32
GSK3B P49841 1/20 0.32
UCHL1 P09936 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
SCN9A Q15858 1/20 0.31
SCN10A Q9Y5Y9 1/20 0.31
LIPG Q9Y5X9 1/20 0.31
HIF1A Q16665 1/20 0.30
PDK2 Q15119 2/20 0.30
HDAC3 O15379 1/20 0.30
HDAC8 Q9BY41 1/20 0.30
NCOR2 Q9Y618 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18530455 0.92 FFAR1 (0.54) FFAR1DGAT1USP30AAK1PRMT5
SCHEMBL31461820 0.91 FFAR1 (0.53) FFAR1DGAT1USP30AAK1PRMT5
SCHEMBL31461761 0.91 FFAR1 (0.53) FFAR1DGAT1USP30AAK1PRMT5
SCHEMBL25248137 0.91 FFAR1 (0.53) FFAR1DGAT1USP30AAK1PRMT5
SCHEMBL24540152 0.89 FFAR1 (0.51) FFAR1DGAT1USP30AAK1PRMT5
SCHEMBL25291902 0.88 FFAR1 (0.50) FFAR1DGAT1USP30AAK1PRMT5
SCHEMBL844227 0.88 FFAR1 (0.60) FFAR1DGAT1USP30AAK1PRMT5
SCHEMBL25245752 0.86 FFAR1 (0.53) FFAR1DGAT1USP30AAK1PRMT5
SCHEMBL3674968 0.86 FFAR1 (0.54) FFAR1DGAT1GSK3AGSK3BUCHL1
SCHEMBL21405360 0.84 FFAR1 (0.51) FFAR1DGAT1USP30AAK1PRMT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109715-A1 IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY (JP) 2026-04-23 US disclosed
EP-4600246-A1 IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE Public University Corporation Yokohama City University (JP) 2025-08-13 EP disclosed
US-20250115598-A1 BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2025-04-10 US disclosed
US-20240383886-A1 Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof ABBVIE INC. 2024-11-21 US disclosed
EP-4452978-A1 BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2024-10-30 EP disclosed
WO-2024075696-A1 IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE 公立大学法人横浜市立大学 2024-04-11 WO disclosed
WO-2023115150-A1 BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-06-29 WO disclosed
WO-2023115150-A1 BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-06-29 WO disclosed
EP-4077319-A1 PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF Calico Life Sciences LLC (US) 2022-10-26 EP disclosed
WO-2021127586-A1 PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF CALICO LIFE SCIENCES LLC (US) 2021-06-24 WO disclosed
US-8871934-B2 Fluorene compound and pharmaceutical use thereof JAPAN TOBACCO INC. (JP) 2014-10-28 US disclosed
US-20130274240-A1 FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC (US) 2013-10-17 US disclosed
US-20130274240-A1 FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC (US) 2013-10-17 US disclosed
US-8343994-B2 Fluorene compound and pharmaceutical use thereof JAPAN TOBACCO INC. (JP) 2013-01-01 US disclosed
US-8343994-B2 Fluorene compound and pharmaceutical use thereof JAPAN TOBACCO INC. (JP) 2013-01-01 US disclosed
US-8343994-B2 Fluorene compound and pharmaceutical use thereof JAPAN TOBACCO INC. (JP) 2013-01-01 US disclosed
EP-2345629-A1 FLUORENE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES Japan Tobacco, Inc. (JP) 2011-07-20 EP disclosed
US-20100240634-A1 Fluorene Compound and Pharmaceutical Use Thereof JAPAN TOBACCO INC. (JP) 2010-09-23 US disclosed
US-20100240634-A1 Fluorene Compound and Pharmaceutical Use Thereof JAPAN TOBACCO INC. (JP) 2010-09-23 US disclosed
US-20100240634-A1 Fluorene Compound and Pharmaceutical Use Thereof JAPAN TOBACCO INC. (JP) 2010-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240634-A1 Fluorene Compound and Pharmaceutical Use Thereof FH, PCK2, PC FFAR1 554/4885DGAT1 802/4885USP30 4750/4885
US-20240383886-A1 Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof PTPN5, PTPN1, PTPN2 FFAR1 1503/4885DGAT1 2933/4885USP30 276/4885
US-20260109715-A1 IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE SMG1, RACK1, TIA1 FFAR1 3993/4885DGAT1 2314/4885USP30 3377/4885
US-20130274240-A1 FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF FH, PCK2, PC FFAR1 554/4885DGAT1 802/4885USP30 4750/4885
US-20250115598-A1 BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS MLKL, CASP1, CASP9 FFAR1 1395/4885DGAT1 3876/4885USP30 1167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.